BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20222312)

  • 1. [Diagnostic imaging of lymphomas].
    Casasnovas O
    Rev Prat; 2010 Jan; 60(1):53-8. PubMed ID: 20222312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL; Jones RJ; Wahl RL
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomic and functional imaging in the management of lymphoma.
    Al-Nahhas A; Win Z; Al-Sayed Y; Khan S; Singh A; Rubello D; Gishen P
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):251-9. PubMed ID: 17538524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of pediatric lymphomas.
    Abramson SJ; Price AP
    Radiol Clin North Am; 2008 Mar; 46(2):313-38, ix. PubMed ID: 18619383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
    Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of PET/CT to evaluate response to therapy in lymphoma.
    Zanoni L; Cerci JJ; Fanti S
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria).
    Rahmouni A; Luciani A; Itti E
    Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S102-6. PubMed ID: 16361124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma.
    Lustberg MB; Aras O; Meisenberg BR
    Eur J Haematol; 2008 Aug; 81(2):154-6. PubMed ID: 18462255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fat necrosis mimicking B-cell lymphoma: a PET/CT and FDG study.
    Belakhlef A; Jani C; Church C; Fraser R; Lakhanpal S
    Clin Nucl Med; 2008 Apr; 33(4):271-2. PubMed ID: 18356666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound.
    von Falck C; Rodt T; Joerdens S; Waldeck S; Kiesel H; Knapp WH; Galanski M
    Clin Nucl Med; 2009 Aug; 34(8):493-5. PubMed ID: 19617723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma.
    Perry C; Herishanu Y; Metzer U; Bairey O; Ruchlemer R; Trejo L; Naparstek E; Sapir EE; Polliack A
    Eur J Haematol; 2007 Sep; 79(3):205-9. PubMed ID: 17662066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
    Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in Follicular Lymphoma Management.
    Bodet-Milin C; Eugène T; Gastinne T; Frampas E; Le Gouill S; Kraeber-Bodéré F
    J Oncol; 2012; 2012():370272. PubMed ID: 22899920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reticuloendothelium malignancy: current role of imaging.
    Sebastian S; Lucey BC
    Cancer Treat Res; 2008; 143():455-68. PubMed ID: 18619228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma.
    Mato AR; Goy A
    PET Clin; 2012 Jan; 7(1):57-65. PubMed ID: 27157018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.
    Berzaczy D; Haug A; Staber PB; Raderer M; Kiesewetter B; Jaeger U; Kornauth C; Simonitsch-Klupp I; Mayerhoefer ME
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance imaging for lymphoma: pros and cons.
    Lynch RC; Zelenetz AD; Armitage JO; Carson KR
    Am Soc Clin Oncol Educ Book; 2014; ():e388-95. PubMed ID: 24857129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.